Results 121 to 130 of about 25,818 (186)

Neurological adverse events of ROS1 inhibitors for non-small cell lung cancer: data from the FDA adverse event reporting system. [PDF]

Front Neurol
Wei X, Lai Q, Zheng L.
europepmc   +1 more source

Health-related quality of life among anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients treated with first- and next-generation ALK tyrosine kinase inhibitors (TKIs): a systematic review and meta-analysis. [PDF]

Qual Life Res
Huang Y, Chu Q, Wang J, Zhang L.
europepmc   +1 more source

Long-term efficacy and safety of lorlatinib versus alectinib in anaplastic lymphoma kinase-positive advanced/metastatic non-small cell lung cancer: matching-adjusted indirect comparison. [PDF]

J Comp Eff Res
Bauer T, Abrahami D, Polli A, Chu H, Ramachandran P, Chandler C, Tan M, Truscott J, Mazieres J, Garcia CA.   +9 more
europepmc   +1 more source

Comparison of the efficacy based on clinicopathological characteristics and the safety of first-line treatments for patients with advanced ALK rearrangement non-small cell lung cancer: a network meta-analysis. [PDF]

Front Oncol
Li Y, Wen Y, Zhang W, Zhao Y, Zhou L, Zeng X, Kang X, Li L.   +7 more
europepmc   +1 more source

Lorlatinib atypical safety profile in ALK-positive aNSCLC: tips for management from an Italian expert panel. [PDF]

Future Oncol
Ardizzoni A, Cortinovis D, Gori B, Nuzzo A, Pasello G, de Marinis F.   +5 more
europepmc   +1 more source

FDA-approved small-molecule kinase inhibitors [PDF]

, 2015
Clausen, Mads Hartvig, Nielsen, Thomas E., Wu, Peng   +2 more
core   +1 more source

Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial. [PDF]

Future Oncol
Ahn MJ, Delmonte A, Ghosh S, Hochmair M, Yang TY, Yang JC, Han JY, Hansen KH, Wu Y, Wan Y, Lin HM, Kretz J, Hupf B, Kurec AM, Churchill EN, Fram RJ, Cabasag CJ, Goriya V, Zhao Y, Campelo MRG.   +19 more
europepmc   +1 more source

In silico design of natural-based structures as drug candidates to inhibit ROS1 protein. [PDF]

Sci Rep
Maleki M, Fattahi A.
europepmc   +1 more source

BH3 mimetic drugs overcome the microenvironment-induced resistance to crizotinib in ALK+ anaplastic large cell lymphoma. [PDF]

Blood Adv
Pignataro C, Zoppoli P, Cappelli LV, Yoffe L, Moretti M, Izzo M, Mallia S, Kayembe C, Taylor A, Petrillo G, Affinito A, Quintavalle C, De Luca G, Mascolo M, Verde S, Fraticelli A, Ciarrocchi A, Salerno P, De Smaele E, Campese AF, Fragliasso V, Foà R, Merla G, Inghirami G, Condorelli G, Fiore D.   +25 more
europepmc   +1 more source

Cost-effectiveness of iruplinalkib versus crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer patients in China. [PDF]

Front Pharmacol
Zhang W, Lu Y, Dai Z, Wang L, Zhou Y, Lu Y, Chang F.   +6 more
europepmc   +1 more source